Gsa Capital Partners LLP Iovance Biotherapeutics, Inc. Transaction History

Gsa Capital Partners LLP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	BUY	$7.59 - $17.47 $464,697 - $1.07 Million	61,225 New	61,225 $907,000
Q1 2023 May 12, 2023	BUY	$5.53 - $8.22 $226,669 - $336,929	40,989 Added 23.32%	216,782 $1.32 Million
Q4 2022 Feb 13, 2023	BUY	$5.62 - $10.0 $533,995 - $950,170	95,017 Added 117.63%	175,793 $1.12 Million
Q3 2022 Nov 14, 2022	SELL	$9.53 - $13.11 $932,053 - $1.28 Million	-97,802 Reduced 54.77%	80,776 $774,000
Q2 2022 Aug 09, 2022	BUY	$6.38 - $18.33 $1.03 Million - $2.96 Million	161,755 Added 961.51%	178,578 $1.97 Million
Q1 2022 May 11, 2022	BUY	$12.38 - $19.1 $17,641 - $27,217	1,425 Added 9.25%	16,823 $280,000
Q4 2021 Feb 14, 2022	BUY	$16.55 - $27.63 $254,836 - $425,446	15,398 New	15,398 $294,000
Q1 2021 May 10, 2021	SELL	$28.67 - $52.59 $152,553 - $279,831	-5,321 Closed	0 $0
Q4 2020 Feb 03, 2021	BUY	$28.04 - $50.26 $149,200 - $267,433	5,321 New	5,321 $247,000
Q2 2019 Aug 06, 2019	SELL	$9.78 - $24.52 $139,521 - $349,802	-14,266 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$8.41 - $11.26 $107,092 - $143,384	-12,734 Reduced 47.16%	14,266 $136,000
Q4 2018 Feb 12, 2019	BUY	$7.51 - $11.93 $202,770 - $322,110	27,000 New	27,000 $239,000

320

238M

1.27M

1.68M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.74B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.